|Ms. Anna Protopapas||Pres, CEO & Director||727k||N/A||1964|
|Dr. Timothy B. Lowinger||Chief Science & Technology Officer||516k||N/A||1964|
|Mr. Mikhail Papisov Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Brian C. DeSchuytner||Sr. VP of Fin. & Product Strategy||N/A||N/A||1978|
|Mr. Ashish Mandelia||VP, Controller & Principal Accounting Officer||N/A||N/A||1974|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Mersana Therapeutics, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.